CYP2D6 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method

CYP2D6 gene prod met act imp Bld/T-Imp

Definition

The CYP2D6 gene product metabolic activity interpretation is determined by the reporting lab and returned with the structured test results. The Preferred Answer list associated with this term is based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for reporting CYP2D6 gene product metabolic activity (phenotype), which apply to both genetic and enzymatic assays (this LOINC term represents a genetic assay). This specific interpretation would be considered a separate observation made by the lab in addition to the primary reported results (e.g., genotype or measured activity level) and it could be included with other assay-specific observations, which would ideally support the interpretation value. [https://cpicpgx.org/resources.html]

Activ; Actvty; Blood; CPD6; CYP2D; CYP2D@; CYP2D6 gene prod met act imp; CYP2D7AP; CYP2D7BP; CYP2D7P2; CYP2D8P2; CYP2DL1; CYPIID6; Cytochrome p450; cytochrome P450, family 2, subfamily D, polypeptide 6; Debrisoquine hydroxylation gene; Drug metabolism; Gene prod met act imp; HGNC:2629; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Movements; Ordinal; P450C2D; P450DB1; P450-DB1; PCR; Phenotype; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue

9 further terms